Delcath Systems Investor Relations Material
Latest events
Q4 2023
Delcath Systems
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Delcath Systems Inc
Access all reports
Delcath Systems, Inc. is a specialty pharmaceutical company focused on the treatment of primary and metastatic liver cancers in the United States and Europe. The Company is, among other, developing proprietary Melphalan Hydrochloride for Injectable Suspension (MHIS), a technology platform used to administer melphalan HCl, a US Food and Drug Administration-approved chemotherapy drug used to treat primary and metastatic liver cancers.
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States